The type I IFN system in rheumatoid arthritis

Conigliaro, P., Perricone, C., Benson, R.A., Garside, P. , Brewer, J.M. , Perricone, R. and Valesini, G. (2010) The type I IFN system in rheumatoid arthritis. Autoimmunity, 43(3), pp. 220-225. (doi:10.3109/08916930903510914)

Full text not currently available from Enlighten.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by joint inflammation, immune cell infiltration of the synovia, and cartilage/bone destruction. Despite noteworthy progress in the treatment of RA in recent years, many patients remain refractory to current therapeutic strategies that target either the adaptive immune system or mediators of the innate system. Type I interferons (IFNs) play a significant role in regulation of the innate immune system, originally being discovered as part of intracellular immune defence against viral infection. IFNs are pleiotropic cytokines, mediating both immunostimulatory and immunosuppressive effects. IFN-alpha and beta have been detected in RA synovial fluid and tissue and subsequent therapeutic approaches using type I IFN in murine models of arthritis and in human RA have produced different and controversial results. Great interest has been directed toward principally plasmacytoid dendritic cells (pDCs), although also toward myeloid dendritic cells, as sources of type I IFN. Furthermore, manipulation of DC populations in murine RA models demonstrated that pDCs could suppress the development of arthritis and autoimmunity and may offer an attractive therapy for T-cell-mediated autoimmune diseases. Finally, dendritic cells (DCs) are vehicles for the delivery of therapeutic vaccines, and clinical trials are ongoing in RA with "tolerogenic" DC populations. Further, studies on animal models of RA will elucidate how IFN and DCs contribute to the establishment of autoimmune arthritis and the potential for manipulation of these cell populations and products to re-establish the immune tolerance

Item Type:Articles
Keywords:ANIMAL-MODEL autoimmune disease BETA BLOOD CELLS Chronic Clinical trial clinical trials CLINICAL-TRIAL CLINICAL-TRIALS COLLAGEN-INDUCED ARTHRITIS CYTOKINE CYTOKINES DENDRITIC CELLS Development DISEASE DISEASES DISORDER ENGLAND FACTOR-ALPHA FLUID Human IFN-I IMMUNE INFECTION inflammation INFLAMMATORY ARTHRITIS INTERFERON-BETA TREATMENT JOINT LUPUS-ERYTHEMATOSUS MODEL Myeloid PATIENT patients PLASMACYTOID DENDRITIC CELLS PLEIOTROPIC CYTOKINE POPULATION PRODUCT Refractory rheumatoid arthritis RHEUMATOID-ARTHRITIS SELF-TOLERANCE STRATEGY synovial fluid SYNOVIAL-FLUID SYSTEM T-CELLS THERAPIES THERAPY TISSUE Treatment TRIAL trials TUMOR-NECROSIS-FACTOR
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Brewer, Professor James and Garside, Professor Paul and Benson, Dr Robert and Conigliaro, Dr Paola
Authors: Conigliaro, P., Perricone, C., Benson, R.A., Garside, P., Brewer, J.M., Perricone, R., and Valesini, G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Autoimmunity
ISSN:0891-6934

University Staff: Request a correction | Enlighten Editors: Update this record